Astellas Pharma (ALPMY) Short Interest Ratio & Short Volume → Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad) Free ALPMY Stock Alerts $9.48 -0.20 (-2.07%) (As of 05/17/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort Interest Astellas Pharma Short Interest DataCurrent Short Volume83,900 sharesPrevious Short Volume69,800 sharesChange Vs. Previous Month+20.20%Dollar Volume Sold Short$801,245.00Short Interest Ratio / Days to Cover0.1Last Record DateApril 30, 2024Outstanding Shares1,809,660,000 sharesPercentage of Shares Shorted0.00%Today's Trading Volume145,649 sharesAverage Trading Volume297,646 sharesToday's Volume Vs. Average49% Short Selling Astellas Pharma ? Sign up to receive the latest short interest report for Astellas Pharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatALPMY Short Interest Over TimeALPMY Days to Cover Over TimeALPMY Percentage of Float Shorted Over Time Ad Weiss RatingsThe ONE AI Stock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …Click here to see the presentation now. Astellas Pharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/202483,900 shares $801,245.00 +20.2%N/A0.1 $9.55 4/15/202469,800 shares $647,150.70 -59.4%N/A0.1 $9.27 3/31/2024171,800 shares $1.85 million +53.1%N/A0.3 $10.75 3/15/2024112,200 shares $1.21 million +51.6%N/A0.2 $10.83 2/29/202474,000 shares $808,820.00 +9.1%N/A0.2 $10.93 2/15/202467,800 shares $749,190.00 -19.7%N/A0.1 $11.05 Get the Latest News and Ratings for ALPMY and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Astellas Pharma and its competitors with MarketBeat's FREE daily newsletter. 1/15/202468,200 shares $823,856.00 -57.1%N/A0.2 $12.08 12/31/2023159,100 shares $1.89 million +305.9%N/A0.3 $11.90 12/15/202339,200 shares $445,312.00 -14.6%N/A0 $11.36 11/30/202345,900 shares $558,144.00 -7.8%N/A0.1 $12.16 11/15/202349,800 shares $579,921.00 +3.8%N/A0.1 $11.65 10/31/202348,000 shares $609,120.00 +1,197.3%N/A0.1 $12.69 10/15/20233,700 shares $48,248.00 -27.5%N/A0 $13.04 9/30/20235,100 shares $70,635.00 -54.1%N/A0 $13.85 9/15/202311,100 shares $165,501.00 -74.7%N/A0 $14.91 8/31/202343,900 shares $664,646.00 -43.9%N/A0.2 $15.14 8/15/202378,200 shares $1.18 million -38.0%N/A0.3 $15.13 7/31/2023126,200 shares $1.85 million +94.8%N/A0.3 $14.63 7/15/202364,800 shares $933,120.00 +9,157.1%N/A0.2 $14.40 6/30/2023700 shares $10,409.00 -98.3%N/A0 $14.87 6/15/202340,900 shares $659,308.00 -32.2%N/A0.5 $16.12 5/31/202360,300 shares $950,931.00 +61.2%N/A0.3 $15.77 5/15/202337,400 shares $599,522.00 +77.3%N/A0.4 $16.03 4/30/202321,100 shares $316,922.00 +64.8%N/A0.3 $15.02 4/15/202312,800 shares $189,568.00 -60.7%N/A0.1 $14.81 3/31/202332,600 shares $462,757.00 -26.4%N/A0.2 $14.20 3/15/202344,300 shares $610,011.00 -15.8%N/A0.2 $13.77 2/28/202352,600 shares $736,400.00 +310.9%N/A0.2 $14.00 2/15/202312,800 shares $183,936.00 +75.3%N/A0.1 $14.37 1/31/20237,300 shares $107,164.00 -73.7%N/A0 $14.68 1/15/202327,700 shares $404,974.00 -43.7%N/A0.2 $14.62 12/30/202249,200 shares $745,872.00 +278.5%N/A0.5 $15.16 12/15/202213,000 shares $202,410.00 -75.8%N/A0.2 $15.57 11/30/202253,600 shares $828,656.00 -48.9%N/A0.5 $15.46 11/15/2022104,900 shares $1.58 million +88.3%N/A0.4 $15.07 10/31/202255,700 shares $772,002.00 -50.2%N/A0.2 $13.86 10/15/2022111,900 shares $1.49 million +5.3%N/A0.3 $13.33 9/30/2022106,300 shares $1.42 million +544.2%N/A0.2 $13.33 9/15/202216,500 shares $227,205.00 No ChangeN/A0 $13.77 8/15/20222,000 shares $30,600.00 -95.6%N/A0 $15.30POTUS in ‘25 Not Biden/Trump, But (Ad)And I believe when they do take the oath of office, their fingers will be crossed… and America will descend into chaos.Click here now to see my urgent election warning. ALPMY Short Interest - Frequently Asked Questions What is Astellas Pharma's current short interest? Short interest is the volume of Astellas Pharma shares that have been sold short but have not yet been closed out or covered. As of April 30th, investors have sold 83,900 shares of ALPMY short. Learn More on Astellas Pharma's current short interest. Is Astellas Pharma's short interest increasing or decreasing? Astellas Pharma saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 83,900 shares, an increase of 20.2% from the previous total of 69,800 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Astellas Pharma's short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Astellas Pharma: Alnylam Pharmaceuticals, Inc. (2.08%), Teva Pharmaceutical Industries Limited (1.09%), Genmab A/S (0.42%), BeiGene, Ltd. (1.93%), BioMarin Pharmaceutical Inc. (2.06%), Viatris Inc. (3.84%), Merck KGaA (0.53%), Sarepta Therapeutics, Inc. (6.02%), United Therapeutics Co. (9.42%), Dr. Reddy's Laboratories Limited (0.52%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Astellas Pharma stock? Short selling ALPMY is an investing strategy that aims to generate trading profit from Astellas Pharma as its price is falling. ALPMY shares are trading down $0.12 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Astellas Pharma? A short squeeze for Astellas Pharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ALPMY, which in turn drives the price of the stock up even further. How often is Astellas Pharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ALPMY, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: ALNY Short Interest TEVA Short Interest GMAB Short Interest BGNE Short Interest BMRN Short Interest VTRS Short Interest MKGAF Short Interest SRPT Short Interest UTHR Short Interest RDY Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (OTCMKTS:ALPMY) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressThe Next Industry Being Reshaped By AIThe Bull ReportWhy Is Gold On a MASSIVE rally? Huge AlertsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingElon’s New Device is About to Shock the WorldInvestorPlaceMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetry